1
|
Goß AV, Dorneburg C, Mulaw M, Xu C, Landthaler C, Jeremias I, Wei J, Debatin KM, Beltinger C. Abstract 2059: Long-term survival of mice with relapsed ALL treated by oncolytic measles virus is terminated by expansion of persistently infected virus-resistant blasts. Cancer Res 2019. [DOI: 10.1158/1538-7445.am2019-2059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: The prognosis of patients with relapsed and refractory ALL is poor. Oncolytic virotherapy is a promising treatment modality combining cancer cell lysis with immunomodulation.
Aims: To determine whether clinical-grade attenuated measles virus (MV) controls relapsed and refractory ALL in vitro and in vivo, to assess resistance mechanisms and to outline targets for immunotherapy in resistant cells.
Methods: The clinical-grade MV-NIS strain was used. ALL cell lines insensitive to chemotherapy and ALL xenografts derived from patients that had died from their disease were investigated. In vitro, cells were treated with MV-NIS and viability was determined. NSG mice were transplanted with a relapsed ALL PDX. Treatment was started when the leukemic load was high, i.e. when 20-30% blasts were present in the peripheral blood, and when the disease had heavily infiltrated spleen, liver, bone marrow and CNS. One dose of i.v. MV-NIS was given. Peripheral blast counts and survival of mice were determined. At time of death the presence of MV in leukemic infiltrates was determined by immunohistochemistry and qRT-PCR, MV was isolated from blasts and serum, and infectivity of isolated MV was tested on Vero indicator cells. mRNA from the blasts, including the genome of the MV they were infected with (MV is a mRNA virus), was subjected to mRNA sequencing. Gene set enrichment and mutation analyses were performed.
Results: In vitro, MV-NIS effectively killed ALL cell lines insensitive to chemotherapy and cells from relapsed patient ALL. In NSG mice with a high and disseminated load of relapsed patient ALL cells, one injection of i.v. MV-NIS sufficed to rapidly decrease leukemic load leading to long-term survival of the mice. Survival was terminated by late disease exacerbation due to expansion of virus-resistant leukemic cells persistently infected with infectious MV. Genome-wide mRNA sequencing revealed strong enrichment of antiviral pathways in the resistant cells, without mutations in the viral genome that could explain the resistance of the blasts.
Conclusions: MV-NIS is preclinically effective against relapsed and refractory ALL in vitro and, initially, in vivo. Late expansion of virus-resistant cancer cells persistently infected with MV is a phenomenon hitherto not described. The viral and antiviral proteins strongly expressed in these cells, which include cell surface proteins, can serve as targets for subsequent immunotherapy.
Citation Format: Annika V. Goß, Carmen Dorneburg, Medhanie Mulaw, Chun Xu, Christine Landthaler, Irmela Jeremias, Jiwu Wei, Klaus-Michael Debatin, Christian Beltinger. Long-term survival of mice with relapsed ALL treated by oncolytic measles virus is terminated by expansion of persistently infected virus-resistant blasts [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2059.
Collapse
Affiliation(s)
| | | | | | - Chun Xu
- 3Medical School Nanjing University, Nanjing, China
| | | | | | - Jiwu Wei
- 3Medical School Nanjing University, Nanjing, China
| | | | | |
Collapse
|
2
|
Dorneburg C, Goß AV, Fischer M, Roels F, Barth TFE, Berthold F, Kappler R, Oswald F, Siveke JT, Molenaar JJ, Debatin KM, Beltinger C. γ-Secretase inhibitor I inhibits neuroblastoma cells, with NOTCH and the proteasome among its targets. Oncotarget 2018; 7:62799-62813. [PMID: 27588497 PMCID: PMC5325329 DOI: 10.18632/oncotarget.11715] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2016] [Accepted: 08/12/2016] [Indexed: 12/17/2022] Open
Abstract
As high-risk neuroblastoma (NB) has a poor prognosis, new therapeutic modalities are needed. We therefore investigated the susceptibility of NB cells to γ-secretase inhibitor I (GSI-I). NOTCH signaling activity, the cellular effects of GSI-I and its mechanisms of cytotoxicity were evaluated in NB cells in vitro and in vivo. The results show that NOTCH signaling is relevant for human NB cells. Of the GSIs screened in vitro GSI-I was the most effective inhibitor of NB cells. Both MYCN-amplified and non-amplified NB cells were susceptible to GSI-I. Among the targets of GSI-I in NB cells were NOTCH and the proteasome. GSI-I caused G2/M arrest that was enhanced by acute activation of MYCN and led to mitotic dysfunction. GSI-I also induced proapoptotic NOXA. Survival of mice bearing an MYCN non-amplified orthotopic patient-derived NB xenograft was significantly prolonged by systemic GSI-I, associated with mitotic catastrophe and reduced angiogenesis, and without evidence of intestinal toxicity. In conclusion, the activity of GSI-I on multiple targets in NB cells and the lack of gastrointestinal toxicity in mice are advantageous and merit further investigations of GSI-I in NB.
Collapse
Affiliation(s)
- Carmen Dorneburg
- Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany
| | - Annika V Goß
- Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany
| | - Matthias Fischer
- Children's Hospital, Department of Pediatric Oncology and Hematology, University of Cologne, Cologne, Germany
| | - Frederik Roels
- Children's Hospital, Department of Pediatric Oncology and Hematology, University of Cologne, Cologne, Germany
| | - Thomas F E Barth
- Department of Pathology, University Medical Center Ulm, Ulm, Germany
| | - Frank Berthold
- Children's Hospital, Department of Pediatric Oncology and Hematology, University of Cologne, Cologne, Germany
| | - Roland Kappler
- Department of Pediatric Surgery, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-University, Munich, Germany
| | - Franz Oswald
- Department of Internal Medicine I, University Medical Center Ulm, Ulm, Germany
| | - Jens T Siveke
- Department of Internal Medicine, University Hospital Essen, Essen, Germany
| | - Jan J Molenaar
- Department of Oncogenomics, Academic Medical Center, Amsterdam, The Netherlands
| | - Klaus-Michael Debatin
- Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany
| | - Christian Beltinger
- Department of Pediatrics and Adolescent Medicine, University Medical Center Ulm, Ulm, Germany
| |
Collapse
|
3
|
Goß AV, Dorneburg C, Debatin KM, Beltinger C. Targeting pediatric acute lymphoblastic leukemia with oncolytic measles. Klin Padiatr 2016. [DOI: 10.1055/s-0036-1582526] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|